Fig. 2From: Aflibercept in branch retinal vein occlusion as second line therapy: clinical outcome 12 months after changing treatment from bevacizumab/ranibizumab—a pilot studyVisual acuity (median, SD): change from baseline to month 12 (p = 0.375)Back to article page